Loading clinical trials...

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

An Open, Multicenter, Phase III Extension Clinical Trial to Evaluate the Long-term Safety of ASC40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne Vulgaris

NCT06248008•Ascletis Pharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.

Eligibility

Age

18 - 40 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants who have successfully completed a 12-week Phase III study of ASC40-303;
•Have fully understood this research and voluntarily signed the informed consent;
•The fertile male and female subjects of reproductive age agreed to use effective contraception from the time they signed the informed consent until 3 months after the final administration of the investigationa drug;
•Subjects are willing and able to complete the study, understand and comply with the study requirements, comply with the study requirements restrictions and related education, use the investigational drug as prescribed by the physician, and follow up according to the study schedule.

Exclusion Criteria

•Discontinue participation in the ASC40-303 Phase III study for any reason;
•Are receiving/planning to receive any systemic acne medications, systemic retinoids, systemic corticosteroids, or any androgen/antiandrogen therapy (e.g., testosterone, spironolactone);
•Pregnant, nursing, or planning a pregnancy during the study period;
•Have major complications (including clinically significant abnormalities in clinical laboratory tests), mental disorders, or other factors deemed unsuitable for study participation by the investigator.

Locations (1)

Huashan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

April 18, 2024

Primary Completion Date

November 12, 2025

Completion Date

November 12, 2025

Last Updated

December 1, 2025

Enrollment

240

ACTUAL participants

Conditions

Acne

Interventions

ASC40

DRUG

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

NCT07058883

Acne Scars

View study

RECRUITINGNA

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

NCT07406893

Joint ArthroplastyShoulder+2 more

View study

RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Inclusion Criteria

Exclusion Criteria

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

The Suitability of Tience® for Treating Acne Scars

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Efficacy of Combined Fractional Er:Glass and Thulium Lasers Versus Microneedling for Atrophic Acne Scars

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors